Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.432
Neutral
RSI(14)
51.486
Neutral
STOCH(KDJ)(9,3,3)
30.793
Neutral
ATR(14)
1.443
Low Volatility
CCI(14)
-68.576
Neutral
Williams %R
67.462
Sell
TRIX(12,20)
0.379
Sell
StochRSI(14)
52.494
Buy
Search
Trevi Therapeutics Inc
TRVIAdd to Watchlist
17.535USD
+0.355+2.07%
Close 07-24 16:00（ET）Quotes delayed by 15 min
2.25BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+2.07%
5 Days
-8.05%
1 Month
-3.39%
6 Months
+72.76%
Year to Date
+40.06%
1 Year
+122.81%
Key Figures
17.360Open
17.540High
1.65MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.29%Turnover Ratio
17.180Prev. Close
16.920Low
23.52MTurnover
LossP/E Static
12.28P/B
0.00%Div Yield TTM
-31.83%ROA
16.12052wk High
0.78Volume Ratio
-47.91MNet Profit
128.31MShares
-0.3200EPS TTM
1.06Beta
-33.59%ROE
5.38052wk Low
3.61%Amplitude
--Gross Margin
2.25BMarket Cap
-1.35Reward/Risk
3.97%Risk Rate
Trevi Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
12
analysts
Buy
Current Rating
27.545
Target Price
+60.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Trevi Therapeutics Inc
TRVI
12
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
17.405
Buy
MA10
17.603
Sell
MA20
17.964
Sell
MA50
16.013
Buy
MA100
14.481
Buy
MA200
12.947
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Trevi Therapeutics Inc Info
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Ticker SymbolTRVI
CompanyTrevi Therapeutics Inc
CEOGood (Jennifer L)
Websitehttps://www.trevitherapeutics.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
52305.700
+405.700 (+0.78%)
28525.900
+375.500 (+1.33%)
7474.700
+66.600 (+0.90%)
15025.000
+77.000 (+0.52%)
64791.000
+572.000 (+0.89%)
6332.100
+67.600 (+1.08%)
84.065
-5.978 (-6.64%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4088.840
+36.490 (+0.90%)
FAQs
What is the current price of Trevi Therapeutics Inc (TRVI)?
The current price of Trevi Therapeutics Inc (TRVI) is 17.54.
What is the symbol of Trevi Therapeutics Inc?
The ticker symbol of Trevi Therapeutics Inc is TRVI.
What is the 52-week high of Trevi Therapeutics Inc?
The 52-week high of Trevi Therapeutics Inc is 16.12.
What is the 52-week low of Trevi Therapeutics Inc?
The 52-week low of Trevi Therapeutics Inc is 5.38.
What is the market capitalization of Trevi Therapeutics Inc?
The market capitalization of Trevi Therapeutics Inc is 2.25B.
Is Trevi Therapeutics Inc (TRVI) currently rated as Buy, Hold, or Sell?
According to analysts, Trevi Therapeutics Inc (TRVI) has an overall rating of Buy, with a price target of 27.55.
What is the Earnings Per Share (EPS TTM) of Trevi Therapeutics Inc (TRVI)?
The Earnings Per Share (EPS TTM) of Trevi Therapeutics Inc (TRVI) is -0.32.